AZD4785, an antisense oligonucleotide which selectively targets and downregulates all KRAS isoforms, has shown good preclinical efficacy both in in vitro and in vivo models of KRAS mutated MM, both alone or in a combinatory regimen with the PI bortezomib [170]. Here, KRAS is linked to Miyoshi myopathy.